Growth in US markets offset by de growth in other markets defined Q2 for Aurobindo Pharma | Q2 FY22 Result Analysis
Published on 16 November 2021 .Views 12.Comments 0
Share On
Aurobindo Pharma’s revenue struggled as growth in US formulations has been offset by decline in topline for other markets. Also inflationary pressure due to which high raw material cost has led to a bleeding quarter for the company.
Download
